Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB. Van Besien K, et al. Among authors: guarneri d. Leuk Lymphoma. 2019 Jul;60(7):1693-1696. doi: 10.1080/10428194.2018.1543877. Epub 2019 Feb 10. Leuk Lymphoma. 2019. PMID: 30741059
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.
Orfali N, Jhanwar Y, Koo C, Pasciolla M, Baldo M, Cuvilly E, Furman R, Gergis U, Greenberg J, Guarneri D, Hsu JM, Leonard JP, Mark T, Mayer S, Maignan K, Martin P, Opong A, Pearse R, Phillips A, Rossi A, Ruan J, Rutherford SC, Ryan J, Suhu G, Van Besien K, Shore T. Orfali N, et al. Among authors: guarneri d. Leuk Lymphoma. 2021 Jul;62(7):1629-1638. doi: 10.1080/10428194.2021.1881516. Epub 2021 Feb 13. Leuk Lymphoma. 2021. PMID: 33586581
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB. Gomez-Arteaga A, et al. Among authors: guarneri d. Bone Marrow Transplant. 2019 Dec;54(12):2027-2038. doi: 10.1038/s41409-019-0587-0. Epub 2019 Jun 12. Bone Marrow Transplant. 2019. PMID: 31190006 Clinical Trial.
Cord blood transplants supported by unrelated donor CD34+ progenitor cells.
Gomez-Arteaga A, Orfali N, Guarneri D, Cushing MM, Gergis U, Hsu J, Hsu YS, Mayer SA, Phillips AA, Chase SA, Mokhtar AE, Shore TB, Van Besien K. Gomez-Arteaga A, et al. Among authors: guarneri d. Bone Marrow Transplant. 2020 Dec;55(12):2298-2307. doi: 10.1038/s41409-020-0959-5. Epub 2020 Jun 9. Bone Marrow Transplant. 2020. PMID: 32518291
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. Mark TM, et al. Among authors: guarneri d. Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. doi: 10.1016/j.bbmt.2017.03.007. Epub 2017 Mar 8. Biol Blood Marrow Transplant. 2017. PMID: 28285081 Free article. Clinical Trial.
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response.
Chaekal OK, Scaradavou A, Masson Frenet E, Albano MS, Cushing M, Desai P, Dobrila L, Gergis U, Guarneri D, Hsu JM, Lee S, Mayer SA, Phillips AA, Orfali N, Ritchie EK, Roboz GJ, Romeo C, Samuel MS, Shore T, van Besien K. Chaekal OK, et al. Among authors: guarneri d. Blood Adv. 2020 Oct 27;4(20):5146-5156. doi: 10.1182/bloodadvances.2020002805. Blood Adv. 2020. PMID: 33091124 Free PMC article.
Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells-a single-institution experience.
Reich-Slotky R, Cushing MM, Hsu YS, Ancharski M, Rojas JM, Scrimenti LM, Robilio S, Assalone D, Roselli T, Guarneri D, Vasovic LV, Goel R, Shore T, van Besien K. Reich-Slotky R, et al. Among authors: guarneri d. Transfusion. 2018 Feb;58(2):339-344. doi: 10.1111/trf.14409. Epub 2017 Nov 29. Transfusion. 2018. PMID: 29193156
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.
Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Boulad F, et al. Among authors: guarneri d. Haematologica. 2018 May;103(5):770-777. doi: 10.3324/haematol.2017.187047. Epub 2018 Feb 1. Haematologica. 2018. PMID: 29419425 Free PMC article.
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.
Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Boulad F, et al. Among authors: guarneri d. Haematologica. 2018 Sep;103(9):1577. doi: 10.3324/haematol.2018.199414. Haematologica. 2018. PMID: 30171018 Free PMC article. No abstract available.
84 results